Caris Life Sciences (CAI) Gross Profit (2024 - 2026)

Caris Life Sciences' Gross Profit history runs 3 years deep, the most recent figure standing at $214.2 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 256.93% year-over-year to $214.2 million in Q1 2026; TTM through Mar 2026 was $518.4 million, a 56.87% increase from a year earlier, with the FY2025 full-year figure at $549.7 million, up 36.78% from the prior year.
• Gross Profit grew to $214.2 million in Q1 2026 per CAI's latest filing, from $38.2 million in the prior quarter.
• Across five years, Gross Profit topped out at $214.2 million in Q1 2026 and bottomed at $38.2 million in Q4 2025.
• The 3-year median for Gross Profit is $106.5 million (2024), against an average of $106.1 million.
• Across the five-year window, Gross Profit tumbled 69.81% in 2025 and jumped 256.93% in 2026, its largest moves.
• Year by year, Gross Profit stood at $126.6 million in 2024, then tumbled by 69.81% to $38.2 million in 2025, then soared by 460.36% to $214.2 million in 2026.
• Per Business Quant, the three latest CAI Gross Profit figures stand at $214.2 million (Q1 2026), $38.2 million (Q4 2025), and $149.9 million (Q3 2025).